
---
title: '国盛证券：维持药明生物_买入_评级，业绩持续高增长'
categories: 
 - 新媒体
 - 36kr
 - 快讯
headimg: 'https://picsum.photos/400/300?random=5588'
author: 36kr
comments: false
date: Tue, 08 Feb 2022 08:24:50 GMT
thumbnail: 'https://picsum.photos/400/300?random=5588'
---

<div>   
国盛证券发布研究报告称，维持药明生物“买入”评级，预计2021-23年收入为95.42亿元/138.99亿元/195.19亿元，同比增长70%/46%/40%；归母净利润为34.83亿元/51.42亿元/73.21亿元，对应增速为106%/48%/42%；EPS为0.83元/1.22元/1.73元；PE为80x/54x/38x。（新浪财经）  
</div>
            